-
Navigo Proteins Appoints Chris-Carol Bremer as Chief Development Officer
B3Cnewswire
February 07, 2022
Navigo Proteins, a premier protein engineering company developing novel scaffold protein-based affinity ligands called Affilin® molecules from its Precision Targeting Toolbox...
-
Global Recommendations for Colon Cancer Translated into Multiple Languages as NCCN Expands Arabic Resources
prnasia
December 23, 2021
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—today announced the publication of newly-translated recommendations for treating colon cancer in Arabic...
-
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
AmericanPharmaceuticalReview
December 14, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company and Foghorn Therapeutics Inc. announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform...
-
Sanofi invests $180 million equity in Owkin's artificial intelligence and federated learning to advance oncology pipeline
WorldPharmaNews
December 02, 2021
Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer...
-
AbbVie, University of Chicago extend oncology research collaboration
Pharmaceutical-Business-Review
November 15, 2021
AbbVie has extended a collaboration agreement with the University of Chicago until 2025 to support preclinical research in oncology.
-
COPILOT Chief Operating Officer Charles A. Stevens Moderates Patient Access Panel at the Association for Value Based Cancer Care (AVBCC) Summit
prnewswire
October 26, 2021
Charles A. Stevens, JD, MBA, Chief Operating Officer of COPILOT Provider Support Services, a market leading provider of technologically advanced healthcare access solutions, moderated a panel...
-
Kazia Therapeutics to Present at LD Micro Main Event
prnasia
October 13, 2021
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event...
-
NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese
prnewswire
September 13, 2021
During Prostate Cancer Awareness Month the National Comprehensive Cancer Network is announcing up-to-date, translated guidelines featuring recent advances in care for one of the most-common types of cancer
-
Morphic Therapeutic Appoints Nisha Nanda to Board of Directors
firstwordpharma
August 24, 2021
Morphic Therapeutic (Nasdaq: MORF) today announced the appointment of Nisha Nanda, Ph.D., to its Board of Directors. Dr. Nanda currently serves as the chief development officer for Loxo Oncology at Lilly.
-
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
firstwordpharma
August 17, 2021
ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry veteran Steven L. Hoerter to its Board of Directors.